Considering taking supplements to treat aminoglycoside ototoxicity? Below is a list of common natural remedies used to treat or reduce the symptoms of aminoglycoside ototoxicity. Follow the links ...

Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young ...

Hearing loss was associated with an increased risk for Parkinson’s disease over 10 years, but early use of hearing aids reduced this risk, a new study shows.

Ototoxicity and glucose intolerance are rare side effects. Posture can affect the patient's response to a diuretic. Patients with CHF have enhanced renal perfusion when supine, and therefore ...

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing ...

Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~~ Terry Evans Appointed Chief Commercial Officer ~~ Christiana Cioffi, MBA, ...

Monitor with digoxin, colchicine, phenytoin, warfarin. Monitor for azithromycin toxicity (eg, liver dysfunction, ototoxicity) with nelfinavir. Concomitant Class 1A (eg, quinidine, procainamide ...

Looking for cheap stocks (by price, at least)? Find U.S.-listed stocks with a price tag under $10 a share, listed by trailing one-year split-adjusted returns. Prices and return data are based on the ...

Sensorion’s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity ...

Kanamycin sulfate 500mg/vial, 1g/vial; soln for IM inj or IV infusion, intraperitoneal, nebulization, irrigation after dilution; contains sulfites. Obesity: base dose on lean body mass. IM: inject ...

for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001] Technology appraisal guidance 11 December 2024 Apalutamide with ...

Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023- -NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth ...